Minority Representation Needs Improvement in Cancer Trials
An analysis of enrollment incidence ratios revealed that Black and Hispanic patients were both significantly underrepresented in U.S. trials.
An analysis of enrollment incidence ratios revealed that Black and Hispanic patients were both significantly underrepresented in U.S. trials.
Read in-depth coverage of the AUA 2024 Annual Meeting, featuring the latest research and science on urology from GU oncology experts and key opinion leaders.
Read in-depth coverage of the AUA 2024 Annual Meeting, featuring the latest research and science on urology from GU oncology experts and key opinion leaders.
New data has compared the efficacy and safety of neoadjuvant abitrexone with or without docetaxel against RP for patients with locally advanced prostate cancer.
Friday, May 3, 2024 11:11 AM to 11:19 AM · 8 min. (US/Central)
Part 1 covered treatment decision-making during suspected BCR following radical prostatectomy.
Friday, May 3, 2024 9:30 AM to 11:30 AM · 2 hr. (US/Central)
The ARASENS study analyzed the efficacy of darolutamide in combination with ADT and docetaxel for the treatment of mHSPC.
A CR was observed in the first patient with mCRPC to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq.
In those who did not undergo EV treatment, NECTIN4 amplifications were not connected with outcomes.
A new study conducted by an international research team has identified new susceptibility regions that are associated with renal cell carcinoma development risk.